Is This Dow Jones Stock a Buy for Income Investors?
Income investing is a tried-and-true investing strategy. This is because businesses that pay consistent and growing dividends to shareholders are often mature businesses that can't possibly reinvest all their profits into future growth projects.
Replacing Pfizer (NYSE: PFE) as a component of the Dow Jones Industrial Average nearly three years ago, the pharmaceutical company (NASDAQ: AMGN) is among the best dividend payers in its industry. But does that make the stock a buy for income investors seeking dividend growth as well?
Let's dig into Amgen's fundamentals and valuation to get an answer to this question.
Source Fool.com
Amgen Inc. Aktie
310,70 €
0,91 %
Überwältigende Zustimmung für Amgen Inc. mit ausschließlich Buy-Einschätzungen.
Trotz eines Kursziels von 304 €, das unter 310.7 € liegt, ergibt sich für Amgen Inc. ein negatives Potenzial von -2.16%.
